Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Adjuvant chemotherapy for stage II colorectal cancer: the time is right!

Abstract

Colorectal cancer is the second most common cause of cancer death in much of the developed world. Cancer-related mortality is slowly decreasing as a result of better detection and improved surgery. Adjuvant chemotherapy is now considered the standard treatment for stage III colon cancer, and has evolved recently with the introduction of infusional, combination chemotherapy. Adjuvant therapy for stage II colon cancer has been more controversial. Recent trial data suggest, however, that there is a legitimate case for discussing the advantages and limitations with individual patients.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Faivre-Finn C et al. (2002) Colon cancer in France: evidence for improvement in management and survival. Gut 51: 60–64

    CAS  Article  Google Scholar 

  2. 2

    Buyse M et al. (1988) Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 259: 3571–3578

    CAS  Article  Google Scholar 

  3. 3

    Moertel CG et al. (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352–358

    CAS  Article  Google Scholar 

  4. 4

    Moertel CG et al. (1995) Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 13: 2936–2943

    CAS  Article  Google Scholar 

  5. 5

    International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345: 939–944

  6. 6

    International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer J Clin Oncol 17: 1356–1363

  7. 7

    Haller DG et al. (1998) Flurouracil, leucovorin and levamisole adjuvant therapy for colon cancer: Five year final report of INT-0089 [abstract]. Proc Am Soc Clin Oncol 17: a256

    Google Scholar 

  8. 8

    QUASAR Collaborative Group (2000) Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial Lancet 355: 1588–1596

  9. 9

    Cassidy J et al. (2004) Capecitabine versus bolus 5FU/leucovorin as adjuvant therapy for colon cancer (the X-ACT study): Efficacy results of a phase III trial [abstract]. Proc Am Soc Clin Oncol 23: a3509

    Article  Google Scholar 

  10. 10

    Andre T et al. (2003) Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 21: 2896–2903

    CAS  Article  Google Scholar 

  11. 11

    Saini A et al. (2003) Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 88: 1859–1865

    CAS  Article  Google Scholar 

  12. 12

    Andre T et al. (2004) Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer. N Engl J Med 350: 2343–2351

    CAS  Article  Google Scholar 

  13. 13

    Saltz LB et al. (2004) Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803) [abstract]. J Clin Oncol 22 (Suppl): a246

    Google Scholar 

  14. 14

    Van Cutsem E et al. (2005) Randomised phase III trial comparing infused irinotecan/5-flurouracil/folinic acid versus 5FU/FA in stage III colon cancer patients (PETACC III) [abstract]. Proc Am Soc Clin Oncol

  15. 15

    Mamounas E et al. (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17: 1349–1355

    CAS  Article  Google Scholar 

  16. 16

    International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17: 1356–1363

  17. 17

    Gill S et al. (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22: 1797–1806

    CAS  Article  Google Scholar 

  18. 18

    Benson AB III et al. (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22: 3408–3419

    Article  Google Scholar 

  19. 19

    Kerr DJ et al. (2000) Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules—less pain, same gain. QUASAR Colorectal Cancer Study Group. Ann Oncol 11: 947–955

    CAS  Article  Google Scholar 

  20. 20

    Gray RG et al. for the QUASAR Collaborative Group. (2004) QUASAR: A randomized study of adjuvant chemotherapy versus observation including 3238 colorectal cancer patients [abstract]. J Clin Oncol 22 (Suppl): aS3501

    Article  Google Scholar 

  21. 21

    Hawkins N et al. (2002) CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122: 1376–1387

    CAS  Article  Google Scholar 

  22. 22

    Witzig TE et al. (1991) DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 68: 879–888

    CAS  Article  Google Scholar 

  23. 23

    Zhou W et al. (2001) Counting alleles reveals a connection between chromosome 18q loss and vascular invasion. Nat Biotechnol 19: 78–81

    CAS  Article  Google Scholar 

  24. 24

    Khan ZA et al. (2000) P53 mutations in primary and metastatic tumors and circulating tumor cells from colorectal carcinoma patients. Clin Cancer Res 6: 3499–3504

    CAS  PubMed  Google Scholar 

  25. 25

    Wang Y et al. (2004) Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 22: 1564–1571

    CAS  Article  Google Scholar 

  26. 26

    Saltz LB et al. (2004) Irinotecan plus fluorouracil/leucovorin versus fluorouracil/leucovorin alone in stage III colon cancer. Proc Am Soc Clin Oncol 23: a3500

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to David J Kerr.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Glossary

IMPACT

International Multicentre Pooled Analysis of Colon Cancer Trials

QUASAR

QUick And Simple And Reliable

X-ACT

Xeloda in Adjuvant Colon Cancer Therapy

MOSAIC

Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer

PETACC

Pan-European Trials in Adjuvant Colon Cancer

NSABP

National Surgical Adjuvant Breast and Bowel Project

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Midgley, R., Kerr, D. Adjuvant chemotherapy for stage II colorectal cancer: the time is right!. Nat Rev Clin Oncol 2, 364–369 (2005). https://doi.org/10.1038/ncponc0228

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing